Neurobiological biomarkers of response to ketamine
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
As a field, psychiatry is undergoing an exciting paradigm shift toward early identification and intervention that will likely minimize both the burden associated with severe mental illnesses as well as their duration. In this context, the rapid-acting antidepressant ketamine has revolutionized our understanding of antidepressant response and greatly expanded the pharmacologic armamentarium for treatment-resistant depression. Efforts to characterize biomarkers of ketamine response support a growing emphasis on early identification, which would allow clinicians to identify biologically enriched subgroups with treatment-resistant depression who are more likely to benefit from ketamine therapy. This chapter presents a broad overview of a range of translational biomarkers, including those drawn from imaging and electrophysiological studies, sleep and circadian rhythms, and HPA axis/endocrine function as well as metabolic, immune, (epi)genetic, and neurotrophic biomarkers related to ketamine response. Ketamine’s unique, rapid-acting properties may serve as a model to explore a whole new class of novel rapid-acting treatments with the potential to revolutionize drug development and discovery. However, it should be noted that although several of the biomarkers reviewed here provide promising insights into ketamine’s mechanism of action, most studies have focused on acute rather than longer-term antidepressant effects and, at present, none of the biomarkers are ready for clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stress Effects on Neuronal Structure: Hippocampus, Amygdala, and Prefrontal Cortex
McEwen, B. S., Nasca, C., & Gray, J. D. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.171 · Cited by 1,574
Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk
Cohen, S., Janicki-Deverts, D., Doyle, W. J., Miller, G. E., Frank, E., Rabin, B. S., & Turner, R. B. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118355109 · Cited by 1,419 · cited 1×
“However, prolonged episodes of inflammatory stress promote glucocorticoid resistance (Pariante, 2017), which results in persistent elevations of interleukin-1β (IL-1β) and immune activation (Cohen et al., 2012).”
BackgroundLong-term potentiation depends on release of d-serine from astrocytes
Henneberger, C., Papouin, T., Oliet, S. H. R., & Rusakov, D. A. (2010) · Nature · doi:10.1038/nature08673 · Cited by 1,389
Haroon, E., Raison, C. L., & Miller, A. H. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.205 · Cited by 1,000
Miller, A. H., Haroon, E., Raison, C. L., & Felger, J. C. (2013) · Depression and Anxiety · doi:10.1002/da.22084 · Cited by 892
Meta-analysis of sleep disturbance and suicidal thoughts and behaviors
Pigeon, W. R., Pinquart, M., & Conner, K. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11r07586 · Cited by 815
Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy
Peltoniemi, M. A., Hagelberg, N. M., Olkkola, K. T., & Saari, T. I. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0383-6 · Cited by 672
Pariante, C. M. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.04.001 · Cited by 382 · cited 1×
“However, prolonged episodes of inflammatory stress promote glucocorticoid resistance (Pariante, 2017), which results in persistent elevations of interleukin-1β (IL-1β) and immune activation (Cohen et al., 2012).”
BackgroundNeutrophil/lymphocyte ratio and platelet/lymphocyte ratio in mood disorders: A meta-analysis
Mazza, M. G., Lucchi, S., Tringali, A. G. M., Rossetti, A., Botti, E. R., & Clerici, M. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.03.012 · Cited by 326 · cited 1×
“, 2019), a newly recognized hematologic biomarker of peripheral inflammation potentially relevant for depressive disorders (Aydin Sunbul et al., 2016; Mazza et al., 2018).”
BackgroundDo the dissociative side effects of ketamine mediate its antidepressant effects?
Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., Nolan, N. M., Richards, E. M., Brutsche, N. E., Guevara, S., & Zarate, C. A. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.02.017 · Cited by 283 · cited 1×
“in psychotic symptoms as assessed by positive symptoms scores on the Brief Psychiatric Rating Scale, and change in diastolic blood pressure, systolic blood pressure, and heart rate at 40min post-infusion were not associated with later antidepressant response to ketamine (Luckenbaugh et al., 2014).”
Self-citation
Cited by
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
Self-citationKetamine Treatment for Depression: A Review
Yavi, M., Lee, H., Henter, I. D., Park, L. T., & Zarate, C. A. (2022) · Discover Mental Health · doi:10.1007/s44192-022-00012-3 · Cited by 161
“Despite these challenges, studying the mechanistic processes and biomarkers that underlie ketamine’s unique properties has fundamentally changed our understanding of the pathophysiology of mood disorders [87].”
BackgroundSelf-citationNovel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Henter, I. D., Park, L. T., & Zarate, C. A. (2021) · CNS Drugs · doi:10.1007/s40263-021-00816-x · Cited by 142
Self-citationKetamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
Self-citationMedeiros, G. C., Gould, T. D., Prueitt, W. L., Nanavati, J., Grunebaum, M. F., Farber, N. B., Singh, B., Selvaraj, S., Machado-Vieira, R., Achtyes, E. D., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01652-1 · Cited by 75
“There is now a significant number of studies on biomarkers of response to ketamine, most of which consist of blood-based assays [31, 42].”
BackgroundSelf-citation
Metadata
- Venue
- Advances in Pharmacology
- Publisher
- Elsevier
- Published
- 2020
- Volume
- 89
- Pages
- 195-235
- ISSN
- 1054-3589 (ISSN-L)
- OpenAlex
- W3035832173
- Cited by
- 36
- References
- 47
- FWCI
- 12.55
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neurobiological biomarkers of response to ketamine. https://app.cochat.ai/papers/10.1016/bs.apha.2020.05.003
- The paper
- Neurobiological biomarkers of response to ketamine. (2020). Advances in Pharmacology. https://doi.org/10.1016/bs.apha.2020.05.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.